Gurbuz, MustafaAkkus, ErmanSakin, AbdullahUrvay, SemihaDemiray, Atike GokcenSahin, SuleymanCay Senler, Filiz2025-05-102025-05-1020210300-89162038-252910.1177/03008916209698232-s2.0-85095844183https://doi.org/10.1177/0300891620969823https://hdl.handle.net/20.500.14720/6873Guven, Deniz Can/0000-0002-6924-9467; Sakin, Abdullah/0000-0003-2538-8569; Demiray, Atike Gokcen/0000-0003-4397-5468; Ergun, Yakup/0000-0003-4784-6743; Turker, Sema/0000-0001-9040-7266; Sahin, Ahmet Bilgehan/0000-0002-7846-0870; Gurbuz, Mustafa/0000-0001-7680-4142; Kilickap, Saadettin/0000-0003-1637-7390Purpose: Taxane-containing combinations are recommended for the first-line therapy of advanced gastric cancer. It is not known which chemotherapy regimen is the best with trastuzumab for HER2-positive patients. The aim of this study was to compare taxane-containing intensified chemotherapy versus standard chemotherapy in combination with trastuzumab in the first-line treatment of HER2-positive advanced gastric adenocarcinoma. Methods: This study is a retrospective multicenter study of the Turkish Oncology Group. A total of 130 HER2-positive patients with inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma being given chemotherapy plus trastuzumab as the first-line treatment were included from 16 different oncology centers. Trastuzumab combination with intensified chemotherapy including taxane or standard chemotherapy was compared in terms of progression-free survival (PFS), overall survival (OS), and toxicity. Results: There were 108 patients in the standard and 22 patients in the intensified chemotherapy group. PFS of the standard and intensified group were 5.6 months (95% confidence interval [CI] 4.8-6.4) and 5.3 months (95% CI 2.6-8), respectively (p = 0.70). OS of the standard and intensified group were 11.1 months (95% CI 8.3-13.9) and 15.2 months (95% CI 12.7-17.7), respectively (p = 0.03). Repeated analysis excluding patients given any previous therapy revealed similar results. The intensified group had more fever and febrile neutropenia. Conclusion: Trastuzumab combination with intensified chemotherapy provides better OS in first-line treatment of HER2-positive advanced gastric cancer. Further large-scale studies should be performed in HER2-positive patients.eninfo:eu-repo/semantics/closedAccessChemotherapyGastric CancerHer2TrastuzumabArticle1075N/AQ341642333167790WOS:000680238700001